Alembic Pharmaceuticals on Tuesday announced that its joint venture Aleor Dermaceuticals Ltd (Aleor) has received approval from the USFDA for its ANDA Clobetasol Propionate Topical Solution USP, 0.05 per cent. The approved Abbreviated New Drug Application is therapeutically equivalent to the reference listed drug Temovate Topical Solution of Fougera Pharmaceuticals Inc. The drug is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. It had an estimated market size of $33 million in 2018, according to IQVIA. Shares of Alembic Pharmaceuticals slipped 1 per cent at ₹538.40 on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.